HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Harumasa Kasai Selected Research

NMS60

6/2006Evaluation of CH3-DTPA-Gd (NMS60) as a new MR contrast agent: early phase II study in brain tumors and dual dynamic contrast-enhanced imaging.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Harumasa Kasai Research Topics

Disease

2Prostatic Neoplasms (Prostate Cancer)
02/2022 - 01/2019
1Demyelinating Diseases (Demyelinating Disease)
01/2022
1Brain Neoplasms (Brain Tumor)
06/2006
1Neoplasms (Cancer)
06/2006

Drug/Important Bio-Agent (IBA)

1IronIBA
01/2022
1Biological ProductsIBA
01/2022
1Contrast MediaIBA
06/2006
1NMS60IBA
06/2006

Therapy/Procedure

1Radiotherapy
02/2022
1Image-Guided Radiotherapy
01/2019
1Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
01/2019